Bronson Crouch
About Bronson Crouch
Bronson Crouch Chief Executive Officer
Bronson Crouch serves as the Chief Executive Officer, bringing over 15 years of experience in the biotechnology and pharmaceutical industries. His role involves overseeing strategic decision-making and driving business growth within the companies he is associated with. As an entrepreneur and investor, Bronson Crouch has developed a robust portfolio in the biopharma sector, showcasing his expertise in identifying and investing in high-potential opportunities.
Bronson Crouch Managing Partner of Curative Ventures
Bronson Crouch currently holds the position of Managing Partner at Curative Ventures. Curative Ventures is a private equity investment firm focused on biopharmaceutical opportunities. In this role, he plays a crucial part in steering the firm's investment strategy, particularly in identifying promising biotech companies for investment and growth.
Bronson Crouch Biopharma Investments
Bronson Crouch has made significant investments in the biotechnology sector. Notably, he invested in CoStim Pharmaceuticals, Inc., an immuno-oncology-focused biotech company that was acquired by Novartis in 2014. His investment portfolio also includes TCR2 Therapeutics, Inc. (Nasdaq: TCRR), a cell therapy company, and Peloton Therapeutics, Inc., which focused on renal cell cancer and was acquired by Merck in 2019 for $1.1 billion upfront. Additionally, Bronson Crouch has invested in iTeos Therapeutics, Inc. (Nasdaq: ITOS), another immuno-oncology biotech company.
Bronson Crouch Biotechnology and Pharmaceutical Industry Experience
With over 15 years in the biotechnology and pharmaceutical industry, Bronson Crouch has gained extensive experience in these rapidly evolving sectors. His professional journey includes critical roles in various high-impact companies, reflecting his deep understanding of biopharma trends, challenges, and opportunities. His expertise spans across strategic investments and management, contributing to significant growth and successful exits in his investment portfolio.